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Microphthalmia transcription factor (MITF) regulates oste-
oclast function by controling the expression of genes, including
tartrate-resistant acid phosphatase (TRAP) and cathepsin K in
response to receptor activator of nuclear factor-B ligand
(RANKL)-induced signaling. To identify novel MITF target
genes, we have overexpressed MITF in the murine macrophage
cell line RAW264.7 subclone 4 (RAW/C4) and examined the
gene expression profile after sRANKL-stimulated osteoclasto-
genesis. Microarray analysis identified a set of genes superin-
duced byMITF overexpression, includingClcn7 (chloride chan-
nel 7) and Ostm1 (osteopetrosis-associated transmembrane
protein 1). Using electrophoretic mobility shift assays, we iden-
tified twoMITF-binding sites (M-boxes) in the Clcn7 promoter
and a single M-box in theOstm1 promoter. An anti-MITF anti-
body supershiftedDNA-protein complexes for promoter sites in
both genes,whereasMITFbindingwas abolishedbymutationof
these sites. TheClcn7 promoter was transactivated by coexpres-
sion of MITF in reporter gene assays. Mutation of one Clcn7
M-box prevented MITF transactivation, but mutation of the
secondMITF-binding site only reduced basal activity. Chroma-
tin immunoprecipitation assays confirmed that the two Clcn7
MITF binding and responsive regions in vitro bind MITF in
genomicDNA. The expression ofClcn7 is repressed in the dom-
inant negative mutant Mitf mouse, mi/mi, indicating that the
dysregulated bone resorption seen in these mice can be attrib-
uted in part to transcriptional repression of Clcn7. MITF regu-
lation of the TRAP, cathepsin K,Clcn7, andOstm1 genes, which
are critical for osteoclast resorption, suggests that the role of
MITF is more significant than previously perceived and that
MITFmay be amaster regulator of osteoclast function and bone
resorption.
Bone-resorbing osteoclasts are multinucleated cells that are
derived from the hematopoietic myeloid/monocyte lineage.
Normal bone remodeling is controlled by the close interactions
between osteoclasts and osteoblasts, the primary bone-synthe-
sizing cells. The balance between the activities of these two cell
types is controlled by tight transcriptional regulation of both
osteoclast-specific and osteoblast-specific genes alongwith sig-
naling mechanisms that couple the actions of these cells.
Defects in the transcriptional control of osteoclasts can result
in a failure of either cell differentiation or function. The
resulting loss of bone resorption results in the development
of osteopetrosis, a condition characterized by dense brittle
bones and the lack of a marrow cavity. The use of transgenic
gene knock-out mice has elucidated the role of several tran-
scription factors in regulating osteoclast differentiation and
function. Null mutations in PU.1 (1), c-Fos (2), and NF-B
p50/p52 (3–5) all result in osteopetrosis, thereby indicating
that these transcription factors play a critical role in regulat-
ing osteoclast biology.
Microphthalmia transcription factor (MITF)2 has been
shown to be a regulator of osteoclast function by activating
transcription of the osteoclast-overexpressed genes, TRAP and
cathepsin K (6, 7). MITF is a member of the basic helix-loop-
helix-leucine zipper (b-HLH-ZIP) family of transcription fac-
tors. This family is defined by the presence of a DNA-binding
basic region, the HLH motif, and the protein association
leucine zipper domain motif (8). Together with TFEB, TFEC,
and TFE3,MITF forms part of theMiT (Mitf-TFE) subgroup of
the b-HLH-ZIP family. These MiT factors form homodimers
and heterodimers with each other but do not heterodimerize
with b-HLH-ZIP factors of other subfamilies (9). All MiT fac-
tors are expressed in cells of the mononuclear phagocyte line-
age with TFE3 and TFEB being widely expressed in other cell
types but TFEC being restricted to myeloid cells (10).
Homozygous loss-of-function or deletion mutations ofMitf
in the mouse result in an absence of coat pigmentation, deaf-
ness, and microphthalmia (8). Homozygous semi-dominant
mutations in Mitf affect cell types, including osteoclasts, mast
cells, andNK cells (8). Heterozygousmutations of theMitf gene
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in humans result in Waardenburg syndrome type 2a (11) and
Tietz syndrome (12), which are characterized by deafness and
hypopigmentation of the hair, skin, and iris.
The mi mutant allele of Mitf has a 3-bpr deletion, which
removes one of four arginine residues in the basic region that
are necessary for MITF binding to DNA (9, 13). As a result, the
mi/mimouse has a severe defect in osteoclast maturation that
produces profound osteopetrosis. This is characterized by the
lack of a ruffled border, failure to fuse in order to formmultinu-
cleated cells, and ultimately a defect in bone resorption (14, 15).
The osteopetrotic defect in the mi/mi mice therefore results
fromdeficiencies in the terminal differentiation and function of
osteoclasts and differs from other osteopetrotic mouse defects,
including null mutations of PU.1, c-Fos, and NF-B, in which
earlier stages of osteoclast differentiation are affected (1–4).
The activation of MITF in osteoclasts via the phosphoryla-
tion of serine residues is dependent on TRAF6-mediated sig-
naling in response to RANKL binding to its receptor, RANK
(16). Site-directed alanine substitution of Ser-73 or Ser-409
results in transcriptionally inactive MITF, and these residues
are targets of phosphorylation by MAP kinase and RSK-1 (17,
18). In osteoclasts, MITF has been identified as a target of Ser-
307 phosphorylation by p38MAPkinase in response toRANKL
treatment (19).
Transcriptional targets of MITF have been identified at cel-
lular sites where the mutant alleles generate a phenotypic
change, including the following: pigment cells, mast cells, and
osteoclasts. Pigment cell-specific genes include the following:
tyrosinase (Tyr) and tyrosine-related genes, Tyrp1 and Dct/
Tyrp2 (20); melanocortin-1 receptor (21); T-box protein 2 (22);
QNR-71 (23); silver (24); absent in melanoma 1 (25); and B cell
leukemia/lymphoma2 (26).Mast cell-specific genes include the
following:mast cell proteases 2, 4, 5, 6, and 9 (27–31); granzyme
B and tryptophan hydroxylase (32); c-kit (33); nerve growth
factor receptor (34); SgIGSF (35);NDST-2 (36); integrin4 (37);
Bcl-2 (26); andPAI-1 (38). Osteoclast-specific genes include the
following: tartrate-resistant acid phosphatase (TRAP) (6);
cathepsin K (7); OSCAR (39); and E-cadherin (40).
Our aim is the systematic identification of MITF transcrip-
tional target genes in osteoclasts.We propose that this will pro-
vide a unique insight intomature osteoclast function, in partic-
ular the transcriptional regulation of genes associated with
osteoclastic bone resorption. To determine the role of MITF in
mature osteoclast function, we identified genes with high
expression in osteoclast-like cells late in the differentiation
process. One such gene is Clcn7 (chloride channel 7), which is
the major chloride channel expressed in the ruffled border of
the mature osteoclast (41). The expression of Clcn7 was also
affected in cells with dysregulated levels of MITF protein. Dis-
ruption of CLCN7 activity leads to severe osteopetrosis in mice
and humans because of a failure of the osteoclast to secrete acid
(41, 42).
The grey-lethal (gl) murine and human alleles contain a
mutation in the Ostm1 gene and are characterized by severe
osteopetrosis (43). The OSTM1 protein forms a complex with
CLCN7 and as such has been proposed to be a -subunit of
active CLCN7 (44). The osteopetrotic phenotype associated
with Ostm1 mutations may result from the impairment of
CLCN7-dependent acidification of the osteoclast resorption
lacuna (44).
In this study, we report several lines of evidence that MITF
regulates both the Clcn7 and Ostm1 genes during osteoclast
maturation. In particular, reporter gene assays using transfec-
tion of osteoclast-like cells (OCL) coupled with electrophoretic
mobility shift assays provide strong evidence of MITF regula-
tion of the Clcn7 andOstm1 promoters, and chromatin immu-
noprecipitation assays validateMITF binding to theClcn7 pro-
moter. This study also shows that Clcn7 mRNA expression is
repressed in primary osteoclasts derived frommi/mimice and
up-regulated inOCL overexpressingMITF protein. Our obser-
vation that MITF controls the expression of Clcn7 and Ostm1
along with TRAP and cathepsin K suggests that MITF is in fact
amaster regulator of a set of genes required for osteoclast func-
tion and bone resorption.
EXPERIMENTAL PROCEDURES
Materials—Weused the following:G418 (geneticin) (Sigma);
the cytokines used were soluble recombinant human RANKL
(sRANKL) (PeproTech) and human colony-stimulating fac-
tor-1 (a gift from Chiron Corp., Emeryville, CA); the plasmids
used were pEF6 (Invitrogen), pGL2-Basic (Promega, Madison,
WI), and pEGFP-1 (Clontech); the cell lines used were
RAW/C4 cells, a subclone of the RAW264.7 macrophage-like
cell line (ATCC, Manassas, VA (45)); the antibodies used were
mouse anti-V5 antibody (Serotec, Oxford, UK), horseradish
peroxidase-conjugated anti-mouse antibody (Cell Signaling
Technology, Inc. Beverly, MA), goat anti-mouse phycoerythrin
antibody (Molecular Probes), and mouse monoclonal anti-
MITF antibody (NeoMarkers, Freemont, CA). Mice heterozy-
gous for themimutation (B6C3Fe background) were obtained
originally from The Jackson Laboratory (Bar Harbor, ME).
Generation of RAW/C4 Cell Lines Stably Transfected with an
MITF Expression Construct and a TRAP Promoter-eGFP
Reporter—The coding region of the wild type murine Mitf-A
isoform was PCR-amplified using the following primers: sense
primer (5-CGGGTTCTGGTCCAAGTCCCAAGCAG-3)
and antisense primer (5-ACA CGC ATG CTC CGT TTC
TTC-3) with the Mitf-pECE construct as the template. The
PCR product was cloned into the pEF6/V5-His TOPO TA vec-
tor (Invitrogen). A murine 620-bp TRAP promoter-eGFP
reporter construct, described previously, was used to monitor
the activity of the exogenous proteins (6, 46).
RAW/C4 cells were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) containing 4 mM L-glutamine, 50 g/ml
penicillin, 50 g/ml streptomycin (Invitrogen), and 5% heat-
inactivated fetal calf serum (Serum Supreme; BioWhittaker,
Walkersville, MD). The cells were plated at a density of 3 105
cells/ml and cultured for 24 h before harvesting for transfec-
tion. RAW/C4 cells (5 106 cells/transfection) were electropo-
rated at 0.28 kV and 1000 microfarads using a Gene Pulser
(Bio-Rad), whereupon they were centrifuged at 1000 rpm for 5
min and resuspended in 10 ml of culture medium and cultured
at 37 °C. For stable transfection, 2 g of selection plasmid
(pNT-Neo, encoding geneticin resistance), 10 g of expression
plasmid (Mitf/pEF6), and 10 g of reporter plasmid (pTRAP-
eGFP) were used per transfection. After a 24-h recovery period,
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transfected cells were cultured in selection media containing
450 g/ml geneticin for 2 weeks. Colonies resistant to the anti-
biotic were pooled and expanded, and expression was moni-
tored using a combination ofWestern blotting, flow cytometry
analysis, and immunofluorescence. The cell lines generated
were RAW/C4-GFP-pEF6 (empty expression vector) and
RAW/C4-GFP-pEF6-Mitf-A (Mitf isoform-A expression
vector).
Flow Cytometry Analysis of Fluorescently Activated Cells—
Cells were washed with cold phosphate-buffered saline
(PBS), centrifuged at 1000 rpm for 5 min, and resuspended in
0.5 ml of PBS for analysis of green fluorescent protein
expression on a FACSCalibur flow cytometer (BD Bio-
sciences). Data analysis was performed by analyzing 10,000
events for each assay using the Cellquest software package
(BD Biosciences). The fluorescence intensity was divided
into four regions, M1 to M4. M1 was set to encompass the
background level of green autofluorescence exhibited by
99.9% of untransfected control cells; M2, M3, and M4 repre-
sented logarithmic increments of fluorescence intensity
(100-, 1000-, and 10,000-fold above the background, respec-
tively). All events with fluorescence intensity greater than
the M1 region were accepted as cellular eGFP fluorescence
events. The data are presented as shown in Equation 1,
% eGFP-expressing cells M4/M2M3M4 (Eq. 1)
Protein Isolation and Western Blotting—To isolate total cel-
lular protein from cultured stable RAW/C4 cell lines, cells
grown as monolayers were washed twice with PBS, pelleted,
and then lysed with 500 l of lysis buffer (66 mM Tris-HCl, pH
7.4, 2% SDS). Protein lysates were resolved by electrophoresis
on a 0.1% SDS, 12% polyacrylamide gel, and blotted onto a
nitrocellulosemembrane (Immobilon transfermembrane;Mil-
lipore), which was blocked in 5% skim milk in Tris-buffered
saline/Tween 20 (TBS-T) overnight at 4 °C. The V5 expressed
protein tag encoded on the pEF6 vector was detected using a
primary anti-V5 antibody (1:2000 dilution) (Serotec) by incu-
bation for 2 h at room temperature. Membranes were washed
and incubated with a secondary horseradish peroxidase-conju-
gated anti-mouse antibody (1:1000 dilution). Image develop-
ment was performed using an enhanced chemiluminescent
detection kit (Amersham Biosciences).
Immunofluorescence Detection of Exogenous Proteins—
RAW/C4 stable cell lines grown on coverslips were washed
twice with PBS and fixed with 4% paraformaldehyde in PBS.
Cells were permeabilized with 0.1% Triton X-100 in PBS, and
then the cells were washed in PBS containing 0.5% bovine
serum albumin and labeled with primary anti-V5 antibody
(1:2000 dilution) for 2 h. After washing with PBS, primary anti-
body was detected with a secondary goat anti-mouse phyco-
erythrin antibody (1:200 dilution) and incubated for 30 min.
Cells were washed again with PBS and stained with DAPI
(Sigma) for 15min for visualization of nuclei. Cells werewashed
again andmounted onto glass coverslips using DAKOCytoma-
tion fluorescentmountingmedia (Dako Corp., Carpenter, CA).
Fluorescence microscopy was conducted on an Olympus
AX-70 unit, and images were captured with NIH image 1.62
software using a Dage-MTI CCD300RC CCD camera.
Culturing OCLs in Vitro and Tartrate-resistant Acid Phos-
phatase Staining—For 5-day cultures, RAW/C4 cells were
seeded at 3  104 cells in 10-cm tissue culture plastic plates
(Corning Glass) and 5  103 cells/well in 6-well plates. For
7-day cultures, cells were seeded at 1  104 cells in 10-cm
plates, 1.6 103 cells/well in 6-well plates, and 0.5 103 cells/
well in 48-well plates. All wells were pre-coated with 0.1% gel-
atin (Sigma), and cells were grown in medium supplemented
with 50 g/ml ascorbic acid (Sigma), 40 ng/ml sRANKL, and
104 units/ml CSF-1 withmedium changes every 2–3 days. OCL
were observed after 5–7 days in culture. Cells were subse-
quently harvested and separately processed for total RNA
extraction and for nuclear protein extraction. Alternatively,
cells were fixed and stained for the OCL marker TRAP using a
commercially available kit (387-A; Sigma) and scored as
TRAPmultinucleated (more than three nuclei) cells.
Hematopoietic precursors were obtained from the spleens of
wild type mice and the spleens of mi/mi mice. OCLs were
grown in the presence of 80 ng/ml receptor activator of nuclear
factor-B (NF-B) ligand (sRANKL, prepared as described
(19)) and 200 units/ml colony-stimulating factor-1 (CSF-1)
withmedium changes every 3 days. Cells were harvested after 5
days in culture.
RNA Extraction and Quantitative PCR—Total cell RNA was
extracted and purified from cells using the RNeasy mini-kit
(Qiagen, Valencia, CA). Each sample was treated with DNase I
(Ambion, Austin, TX) and reverse-transcribed using a 17-mer
oligo(dT) primer and the Superscript III RNase H reverse tran-
scriptase kit or Superscript III first-strand synthesis system for
reverse transcription-PCR (Invitrogen) according to the man-
ufacturer’s instructions. Negative control samples (no first-
strand synthesis) were prepared without the addition of reverse
transcriptase. The cDNA was diluted to 100 l with water, and
4l was used for quantitative real time PCR (qPCR) performed
using the LightCycler-DNA Master SYBR Green I kit (Roche
Applied Science). The PCR was performed using an ABI Prism
thermal cycler (Applied Biosystems) as follows: 1 min hot start
at 94 °C; 45 cycles of 15 s at 94 °C, 10 s at 60 °C, and 15 s at 72 °C.
cDNA levels during the linear phase of amplification were nor-
malized against Hprt (hypoxanthine phosphoribosyltrans-
ferase) controls. Assays were performed in triplicate, and the
means S.D. were determined. Specific primers were used for
qPCR as follows:mouse TRAP1C (GenBankTM accession num-
ber NM_007388) forward primer (5-ACC TGT GCT TCC
TCC AGG AT-3) and reverse primer (5-TCT CAG GGT
GGG AGT GGG-3); mouse cathepsin K (GenBankTM acces-
sion number NM_007802) forward primer (5-CCATATGTG
GGC CAGGATG-3) and reverse primer (5-TCA GGGCTT
TCT CGT TCC C-3); mouse Clcn7 (GenBankTM accession
number NM_011930) forward primer (5-GAC TGG CTG
TGG GAA AGG AA-3) and reverse primer (5-TCT CGC
TTG AGT GAT GTT GAC C-3); mouse Ostm1 (GenBankTM
accession number NM_172416) forward primer (5-TTGGAC
AATTAGTTCTATCATCG-3) and reverse primer (5-GCC
GGA CTG TAA CAG ATA GCT-3). The relative expression
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levels were calculated using experimentally determined primer
efficiency and the CT method (47).
Microarray Analysis and Data Handling—The microarray
experiment was performed using 17.5 days post-coitum
C57Bl/6J embryo total RNA as a common reference (48).
Microarray experiments were performed in duplicate using
independently generated RNA from OCL generated from the
stable cell lines treated with sRANKL/CSF-1 for 5 days and
untreated stable cell lines. The RNAwas directly labeled during
cDNA synthesis with amino allyl-conjugated Cy3 (sample) or
Cy5 (embryo), as described on line, and hybridized at 42 °C
overnight to 22,000 elementmouse Compugen oligonucleotide
microarrays (SRC, Microarray Facility). Slides were washed for
5 min in 2 SSC, 0.2% SDS buffer and scanned on a ScanArray
5000 confocal laser scanner. MolecularWare software (Digital
Genome) was used to process the image, and data were cor-
rected for local background, and confidence status was flagged
for empty spots, signal/noise ratio, spot ratio variability, and
spot morphology. Data were imported into the GeneSpring 4.2
software (Silicon Genetics) for clustering and comparative
analysis.
Bioinformatic Extraction of 5 Upstream Sequences of Com-
pugen Array Gene List and Blast Analysis for Consensus MITF-
binding Sites—The hypothetical promoters (2 kb upstream of
the translation start site as defined in Ensembl) of all the genes
on the 22,000 element Compugen array were extracted into a
sequence-formatted file. String matching was employed to
parse each promoter for the presence ofM-box (TCANNTGA)
motifs. This process entailed a 5 to 3 progression for each
promoter sequence, with each position n receiving a score
based on the agreement between each motif position i and the
corresponding promoter sequence positionn i, where i 0.7.
For eachmotif position i, amatch was worth 1, and amismatch
was worth 0. If the total score for the promoter sequence posi-
tion n was equal to 8, a positive match was recorded for that
position.
Analysis of Promoter Activity—RAW/C4 cells (5 106) were
transfected with endotoxin-free plasmid preparations (Qiagen)
by electroporation. Cells were electroporated (280 V/1millifar-
ads; Gene-Pulser, Bio-Rad) with 10 g of reporter plasmid and
2g of expression plasmid in 250l of completemedia supple-
mented with 10 mM HEPES (Thermotrace, San Diego). Cells
were electroporated immediately after the addition of plasmid
DNA and washed without delay after transfection to limit
RAW264.7 activation by the plasmid DNA (49). After electro-
poration, the cells were divided into 2 or 4 wells of a 6-well
tissue culture plate (Iwaki, Japan) and were cultured for 24 h
before harvesting the cells. The cellular harvest and luciferase
activity assay were performed using the Luclite luminescence
reporter gene assay system (PerkinElmer Life Sciences) accord-
ing to the manufacturer’s instructions. Briefly, transfected cells
werewashed twicewith cold PBS and extracted in the platewith
150 l of 1 lysis buffer for 15 min. Cellular debris was
removed by centrifugation, whereupon 50l of lysate superna-
tant was transferred into alternate wells of a 96-well Trilux
Optiplate and assayed for luciferase activity by the addition of
50 l of luciferase assay reagent. Light emission was measured
with a Packard TriLux luminometer using Microbeta worksta-
tion software. Luciferase activity was normalized to the total
protein concentration of the cell lysate asmeasured by the BCA
assay kit (Pierce) to give relative light units per g of protein.
The mean  S.E. was calculated within and between
experiments.
Electrophoretic Mobility Gel Shift Assays (EMSA)—Nuclear
extracts for EMSAswere prepared by hypotonic lysis at 4 °C.All
buffers contained phosphatase inhibitors (1 mM sodium vana-
date, 1 mM sodium pyrophosphate, 1 mM sodium molybdate,
and 10 mM sodium fluoride) and a 1 protease inhibitor mix-
ture (complete, mini, EDTA-free; Roche Applied Science) in all
steps of nuclear extract preparation. Cells were harvested and
washed twice in PBS. The pellet was resuspended in 1 ml per
10 106 cells of buffer A (10 mM HEPES, pH 7.6, 10 mM NaCl,
0.5 mM EDTA, 0.5 mM EGTA, 0.5 mM DTT, 0.5 mM PMSF).
Cellular swelling was observed using phase-contrast micros-
copy. 0.5 ml per 10  106 cells of buffer B (25 mM HEPES, pH
7.6, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.6% Nonidet
P-40, 2 mMDTT, 1mM PMSF) was added, and the solution was
immediately vortexed at low speed for 30 s. Nuclei, free of cyto-
plasm, were apparent using light microscopy. The nuclei were
pelleted, and the supernatant was removed completely. The
nuclei were resuspended by addition of 100 l of buffer C per
1  106 cells (25 mM HEPES, pH 7.6, 350 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 20% glycerol, 1 mM DTT, 0.5 mM PMSF)
dropwisewhile flicking the tube. Nuclei were shaken vigorously
in the high salt buffer for 20 min. Cellular debris was removed
by centrifugation.
Complementary oligonucleotides used for double-stranded
probe preparation were as follows with mutated residues
shown in lowercase: (sense strand) TRAP from 	582 to 	549
relative to the ATG (5-CAG TTC TGGGGAAGTCCAGTG
CTC ACA TGA CCC A-3) and TRAPE (5-CAG TTC TGG
GGA AGT CCA GTG CTc tcg agA CCC A-3); Clcn7 oligo 1
(5-CGT GCA GCC ATA TGA AAT TTT ATT GT-3) and
Clcn7 oligo 1E (5-CGT GCA GCc tcg agA AAT TTT ATT
GT-3); Clcn7 oligo 2 (5-CAC AGG AAA CAC ATG AAG
CCAACTTA-3) andClcn7 oligo 2E (5-CACAGGAAA ctc
gag AAG CCA ACT TA-3); Clcn7 oligo 3 (5-CGT CGT CAG
TCA CGT GGG CAC CGA TG-3) and Clcn7 oligo 3E (5-
CGT CGT CAG Tct cga gGG CAC CGA TG-3); Clcn7 oligo 4
(5-CCG ATG ATA GAT CAC GTG AGA CCT GGG-3) and
Clcn7 oligo 4E (5-CCG ATG ATA GAT ctc gag AGA CCT
GGG-3); and Ostm1 oligo (5-CAG TTC TGG GGA AGT
CCAGTGCTCACATGACCCA-3) andOstm1E (5-CAG
TTC TGG GGA AGT CCA GTG CTc tcg agA CCC A-3).
Oligonucleotides were 5 end-labeled with [-32P]ATP and
T4 polynucleotide kinase for 30 min at 37 °C. Nuclear extract
proteins were bound to the DNA probe in a 10-l reaction
containing 20mMHEPES, pH7.9, 500 nMDTT, 2mMEDTA, 40
mMKCl, 12% glycerol, 1g of salmon spermDNA, 0.04 pmol of
purified probe, and 2 g of nuclear extract. Reactions in which
competitor probes were added included 10-, 50-, or 100-fold
molar excess of unlabeled competitor probe (0.4, 2, or 4 pmol,
respectively). The supershift reaction included the anti-MITF
antibody (NeoMarkers). The Tris-glycine/EDTA gel system
was used for EMSA analysis; 6% acrylamide/bisacrylamide gels
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(29:1) were polymerized by the addition of 0.1% w/v ammo-
nium persulfate and 0.2% TEMED in 0.15 M Tris-HCl, pH 8.8.
Chromatin Immunoprecipitation (ChIP) Assay—To cross-
link proteins to genomic DNA at indicated time points, form-
aldehyde was added to a final concentration of 1% to 2  106
bonemarrow-derived cells treated with 40 ng/ml sRANKL, 1
104 units/ml CSF-1 and incubated at 37 °C for 10 min. The
reaction was stopped by the addition of 125 mM glycine. The
nuclei were isolated by resuspension in PIPES nuclei isolation
buffer (5 mM PIPES, pH 8.0, 85 mM KCl, 0.5% Nonidet P-40, 1
g/ml antipain, 1 g/ml aprotinin, 1 g/ml leupeptin, 1 mM
PMSF, and phosphatase inhibitors where appropriate) by incu-
bation on ice for 10min and pelleting down at 500 g for 5min
at 4 °C. Soluble chromatin of an average size of 200–1000 bp
was prepared using 30 cycles of 10-s pulses followed by a 20-s
pause in a Branson 250 sonicatorwith a taperedmicrotip at 45%
power. The chromatin was first precleared with protein G
beads (Invitrogen) equilibratedwith bovine serum albumin and
yeast tRNA, and 10% of the soluble chromatin was set aside as
input, and the rest of chromatin was immunoprecipitated with
5 g each of anti-MITF or anti-PU.1 antibody. The immuno-
precipitated DNA-protein complex was washed, eluted,
decross-linked, treated with RNase A and proteinase K, and
purified by Qiagen PCR purification kit according to the man-
ufacturer’s instructions.
RESULTS
ExogenousMITF Is Expressed in Stably Transfected RAW/C4
Cell Lines—To increase MITF expression in OCLs, a subclone
of the osteoclastogenic RAW264.7 cell line (RAW/C4) was sta-
bly transfected to overexpress wild type MITF. RAW/C4 cells
have an increased potential to form OCLs compared with the
parent RAW264.7 cell line (45). MITF was cloned with a 3 V5
epitope tag in the pEF6 mammalian expression plasmid, under
the control of the EF1 promoter (50). The pEF6 and MITF/
pEF6 plasmids were transfected separately into RAW/C4 cells
together with the TRAP promoter reporter plasmid (pTRAP-
eGFP) and pNT-Neo. Stable transfectants were selected using
G418 and the resulting cell lines,
RAW/C4-GFP-pEF6 andRAW/C4-
GFP-Mitf/pEF6, were maintained
as pools of clones rather than iso-
lated clones to obviate insertion
positional effects.
Expression of the pEF6-derived
Mitf-V5 mRNA was detected by
reverse transcription-PCR in the
RAW/C4-GFP-Mitf/pEF6 cell line
alone (Fig. 1A). Western blotting of
native extracts of these cell lines
using an anti-V5 antibody detected
a 61-kDa protein, which was con-
sistent with the size predicted for
Mitf-V5 (Fig. 1A). Immunocyto-
chemical staining of RAW/C4-
GFP-Mitf/pEF6 and RAW/C4-
GFP-pEF6 cells using anti-V5
antibody confirmed that exogenous
V5-tagged MITF is expressed, and its intracellular localization
to the nucleus was confirmed byDAPI nuclear counter staining
(Fig. 1B).
Overexpression of MITF Increases OCL Number and Increases
Expression of Known MITF Target Genes—The phenotypic out-
come of MITF overexpression was determined when RAW/C4-
GFP-Mitf/pEF6 cells were induced to form OCL by treatment
with sRANKL andCSF-1. RAW/C4-GFP-Mitf/pEF6 cells formed
OCLs that were larger and more strongly TRAP-positive than
RAW/C4-GFP-pEF6cell-derivedOCLs (Fig. 2A). In aquantitative
measurement of TRAP-positive, multinucleated cell formation
(3 nuclei/cell), RAW/C4-GFP-Mitf/pEF6 cells were found to
have a slightly greater potential to form OCLs than RAW/C4-
GFP-pEF6 cells (Fig. 2B).
All cell lines were cotransfected with a murine TRAP pro-
moter-eGFP reporter construct (pTRAP-eGFP) as an internal
validated target ofMITF activity. This construct incorporated a
620-bp fragment of the proximal murine TRAP 1C promoter
that has been shown previously to be MITF-responsive (46),
and flow cytometry was used to detect eGFP fluorescence. Flu-
orescence of eGFP was undetectable in the RAW/C4-GFP-
pEF6 and RAW/C4 cell lines, whereas fluorescence was
detected in the RAW/C4-GFP-Mitf/pEF6 cell line when exam-
ined with an Olympus IX-70 microscope using a fluorescein
isothiocyanate filter (Fig. 2C). Flow cytometry was used to
quantitate eGFP expression levels and determined that cells
overexpressing MITF had a 2.5-fold increase in eGFP expres-
sion compared with the RAW/C4-GFP-pEF6 and RAW/C4-
GFP cell lines (Fig. 2D).
Having confirmed that MITF overexpression in RAW/C4
cells is capable of regulating the expression of an exogenous
TRAP promoter construct, we then examined the effect of
MITF overexpression on the levels of endogenous genes. TRAP
and cathepsin K mRNA levels were measured by qPCR before
and after treatment of the cells with sRANKL and CSF-1 for 5
days.
The expression of endogenous TRAP in RAW/C4-GFP-
Mitf/pEF6 cells on a macrophage background in the absence of
FIGURE 1. Expression ofMITF-V5 in RAW264.7/C4 cells (RAW/C4 cells). A, reverse transcription-PCR forMitf
transgene in stably transfected RAW/C4 cells using vector 5 primer and Mitf reverse 3 primer (lane 1). RNA
from RAW/C4-pEF6 cell lines was used as a negative control (lane 2). Anti-V5 Western blot of total cell lysates
from stably transfected RAW/C4 cells demonstrating MITF protein construct expression (lane 4). Cell lysates
were resolved by SDS-PAGE and probed with anti-V5. Cell lysates from untransfected RAW/C4 cells and RAW/
C4-pEF6 cells served as negative controls (lanes 3 and 5, respectively). B, detection of V5 epitope tagged MITF
construct by immunofluorescence in stably transfected RAW/C4 cells using anti-V5 and phycoerythrin (PE)-
conjugated anti-mouse antibodies. DAPI nuclear counter staining confirms MITF nuclear localization. The V5
epitope was undetectable in the RAW/pEF6 cell line.
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RANKL was 2.2-fold higher than in
cells not overexpressing MITF,
whereas cathepsin K was 3.2-fold
higher (Fig. 2E). Following treat-
ment of the vector control with
sRANKL and CSF-1, endogenous
TRAP expression was induced 21.4-
fold, whereas cathepsin K expres-
sion was induced 95.1-fold. In the
RAW/C4-GFP-Mitf/pEF6 cells fol-
lowing sRANKL and CSF-1 treat-
ment, TRAP expression was super-
induced a further 4.1-fold higher,
whereas cathepsin K expressionwas
superinduced 2.3-fold.
The superinduction of these
genes in the RAW/C4-GFP-Mitf/
pEF6 cell line suggests that a similar
superinduction may occur with
other MITF target genes. This sug-
gests that increasing the level of
MITF protein can result in a sec-
ondary increase in the level of acti-
vated phospho-MITF, which in turn
can have a downstream effect on its
transcriptional targets that can then
bemonitored using expression-pro-
filing techniques.
Microarray and Bioinformatic
Analysis of Genes Superinduced
by MITF Overexpression during
RAW/C4-derived Osteoclastogenesis—
Phenotypic analysis of RAW/C4
cells in which the protein levels of
MITF have been modulated has
demonstrated that this is an effec-
tive cellular model to study MITF
transcriptional targets. Microarray
expression profiling of these cells
was used to perform a global search
for novel targets of MITF that are
superinduced. RNA was harvested
from RAW/C4-GFP-Mitf/pEF6 and
RAW/C4-GFP-pEF6 cells on amac-
rophage background (untreated) or
an OCL profile (5-day treatment
with sRANKL and CSF-1) for this
experiment. Labeled cDNA pre-
pared from RAW/C4-GFP-Mitf/
pEF6 and RAW/C4-GFP-pEF6 cells
was hybridized to 22,000 element
Compugen murine array chips, and
the pattern of gene expression was
analyzed.
In parallel to the microarray
experiment, a bioinformatic analy-
sis was undertaken to identify genes
present on theCompugen array that
FIGURE 2. Overexpression of MITF up-regulates osteoclast formation and increases the expression of
knownMITF targets TRAP and cathepsin K. A,multinucleated OCLs derived from RAW/C4 cell stably trans-
fected with MITF and empty vector (pEF6). B, quantitation of TRAP-positive multinucleated cells (
3 nuclei)
following culture for with sRANKL/CSF-1. Bars represent means  S.E. (n  9). C, eGFP expression in stably
transfected RAW/C4 cells using a TRAPpromoter-eGFP reporter construct. Imageswere visualized on anOlym-
pus IX-70microscope using a fluorescein isothiocyanate filter and fluorescence specific to those cells express-
ing exogenousMITF.D, flow cytometry has been used to quantitate eGFP expression in stably transfected cells
overexpressingMITF and TRAPpromoter eGFP-reporter constructs. Bars representmeans S.E. (n 9). E, cells
overexpressing MITF have a 2–3-fold increase in endogenous expression of both genes on a macrophage
background (	sRANKL) comparedwith the vector control. TRAP and cathepsin K expression is increased (21.4-
and 95.1-fold, respectively) following 5-day culture with sRANKL and CSF-1 in RAW/C4 cells (sRANKL). Cells
overexpressingMITF showedan increase in both TRAPand cathepsin K expression 2–4-fold higher than vector
control cells (“superinduction”) under the same conditions. Experiments were performed in triplicate, and the
bars represent the S.D. for one experiment.
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contain consensus MITF-binding sites. A blast technique was
undertaken to download 2 kb of genomic DNA sequence 5 to
the annotated translation start site for all genes represented on the
Compugen array. These hypothetical promoter regions were
searched for the presence of MITF-specific binding sites. MITF
has been shown to bind to E-boxes (CANNTG) with affinity sim-
ilar to other bHLH-ZIP transcription factors butwith a preference
for an additional T on the 5 end or an A on the 3 end (51). The
bioinformatic approach utilized a blast algorithm to search for the
sequence TCANNTGA (M-box; the additional defining nucleo-
tides are underlined) in the hypothetical promoter regions of all
the genes on the Compugen array.
The sample gene expression data were normalized against
data from 17.5 days post-coitum embryo total RNA and filtered
to remove uninformative spot data. The genes that passed fil-
tering were analyzed for elevated expression relative to the
embryo RNA, which produced a list of 3,700 genes. This gene
list was compared with the gene list from the bioinformatic
analysis of the Compugen gene regulatory regions containing
candidateM-boxes (Fig. 3A). The working list of genes that was
FIGURE 3. Identification of genes superinduced by MITF overexpression during osteoclast differentiation in RAW/C4 cells. Microarray analysis of
analysis was performed using themurine Compugen 22,000 element array chips on RAW/C4, RAW/C4-pEF6, and RAW/C4-Mitf/pEF6 cell lines either untreated
(0 days) or treated with 40 ng/ml sRANKL and 104 units/ml CSF-1 (5 days). In parallel, a bioinformatics analysis was undertaken to identify candidate M-box-
containing genes. A large scale Blast technique has been developed to download 2 kb of DNA sequence 5 of the translation start site for all the genes on the
array. These promoter regions were searched for the presence of an extendedMitf-binding E-box consensus sequence (TCANNTGA), termed the M-box.
A, Venn diagram compares the total genes on the array to the selected genes with high expression compared with embryo RNA (filtered genes) and to genes
containing M-boxes. Common to all three groups is a list of 759 M-box containing genes with high expression on the array profile. B, data revealed a set of
up-regulated genes following treatment with RANKL that were superinduced in cells overexpressing MITF. A list of 128 superinduced genes in MITF overex-
pressing cells was reduced to 25 on the basis of excluding genes without MITF-binding sites. C, expressions of TRAP, Clcn7, andOstm1mRNAs are induced by
sRANKL treatment of RAW/C4 cells for 5 days and superinduced by MITF overexpression. The microarray data were consistent with qPCR quantitation, and
bioinformatics analysis identified Clcn7 and Ostm1 with a similar expression response. Clcn7 and Ostm1 are also induced by sRANKL treatment and are
superinduced in cells overexpressing MITF.
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produced after excluding genes that did not meet these criteria
was reduced from 22,000 gene expression profiles available for
inspection on the array to a list of 759 expression profiles.
In addition to this filtering process, gene lists were sorted on
a basis of fold-induction following treatmentwith sRANKL and
CSF-1. Genes that were induced following treatment with
sRANKL and CSF-1 were compared between two conditions,
RAW/C4-GFP-Mitf/pEF6 (sRANKL) and RAW/C4-GFP-
pEF6 (sRANKL) (Fig. 3B). Genes with transcript abundance
at least 2-fold higher in the sRANKL-treated RAW/C4-GFP-
Mitf/pEF6 cells compared with the RAW/C4-GFP-pEF6 cell
line were selected for further analysis. This screen, based on
fold-induction, produced a list of 128 genes that were “superin-
duced” by MITF expression in addition to sRANKL treatment.
After excluding genes without M-boxes, this list was further
reduced to 25 genes (Table 1). TRAP and cathepsin K were
present in this short list of potential MITF-regulated genes,
which are known osteoclast targets ofMITF, and their presence
validates this profiling approach. The microarray expression
profiles of TRAP, Clcn7, and Ostm1 display up-regulation of
gene expression following culturewith sRANKL andCSF-1 and
further superinduction in cells overexpressing MITF (Fig. 3C).
qPCR confirmed that Clcn7 and Ostm1 mRNA levels are
induced following treatment with sRANKL and CSF-1 in
RAW/C4-pEF6 cells and further induced in theRAW/C4-GFP-
Mitf/pEF6 cell line (data not shown).
Time Course of Clcn7, Ostm1, and TRAP Expression and
Identification of Promoter M-boxes—The up-regulation of
TRAP,Clcn7, andOstm1 expressionwas examined in RAW/C4
cells over a 7-day time course of treatment with sRANKL and
CSF-1. qPCR analysis of gene expression showed that both
Clcn7 (Fig. 4B) and Ostm1 (C) were up-regulated with similar
kinetics to TRAP (A), a known target of MITF.
A comparison of the mouse and human Clcn7 promoter
revealed four candidate M-boxes and numerous Ets transcrip-
tion factor-binding sites (GGAA) located between 	731 and
80 bp on both the forward and reverse strands of the proximal
mouse promoter (Fig. 5A). Examination of the mouse Ostm1
promoter revealed one candidate M-box, three E-boxes, and
numerous Ets transcription factor-binding sites located
between 	534 and 70 on both the forward and reverse
strands of the proximal promoter (Fig. 5B).
Clcn7 mRNA Levels Are Reduced in mi/mi Osteoclasts—
Clcn7mRNA expression is induced by overexpression ofMITF
protein in RAW/C4 cells, but is Clcn7 expression affected in
OCLs derived frommi/mimice? Themi/mimouse has a dom-
inant negative mutation in MITF such that it is able to bind to
its dimerization partners without activating transcription of
known targets like TRAP and cathepsin K, therefore rendering
MITF, as well as its partners, functionally inactive.
TRAP and Clcn7 mRNA levels were measured by qPCR in
RNA preparations of cells from wild type and mi/mi spleens
cultured with sRANKL and CSF-1. Expression of both TRAP
andClcn7 increase over a period of 5 days in culture, consistent
with genes that are induced during osteoclastogenesis (Fig. 6).
In bone marrow-derived OCL differentiated in vitro from
mi/mimice, the induction of both TRAP and Clcn7 is ablated,
but the basal expression of Clcn7 is not diminished.
MITF Binds to the Clcn7 Promoter—To establish whether
MITF directly transcriptionally regulates Clcn7 expression in
osteoclasts, the ability ofMITF to bind to theClcn7promoter in
primary and RAW/C4-derived OCLs was determined. Experi-
ments validating the direct interaction of MITF with potential
targets in a functional manner are well established in cell line
models, including RAW264.7 cells (6, 7, 10, 19, 39, 46, 52).
ChIP assays for MITF and the Ets transcription factor, PU.1,
which can act as a transcriptional coactivator with MITF, were
performed on nuclear extracts from wild type bone marrow
cells following treatment with sRANKL and CSF-1 in culture
over a time course of 5 days. qPCR amplification of the region
containing M-boxes on chromatin cross-linked to anti-MITF
or anti-PU.1 antibodies revealed that bothMITF and PU.1were
bound to the endogenous Clcn7 promoter region with
increased abundance over the 5-day time course (Fig. 7A). The
TABLE 1
Genes superinduced by the overexpression of MITF during RAW/C4 osteoclastogenesis that contain candidate promoter M-boxes
Array identifier GenBankTM accession no. Gene name Description
3003011_1 NM_008218 Hba1 Hemoglobin-, adult chain 1
3002492_1 NM_007606 Car3 Carbonic anhydrase 3
3003286_1 NM_011930 Clcn7 Chloride channel 7
3002170_1 NM_007802 Ctsk Cathepsin K
3002283_1 NM_008455 Kikb1 Kallikrein B, plasma 1
EXT_3106903_1 NM_013660 Sema4d Sema domain, immunoglobulin domain (Ig)
3001911_1 NM_015774 Ero1l ERO1-like (S. cerevisiae)
3006519_1 NM_011518 Syk Spleen tyrosine kinase
3005446_1 NM_009856 Cd83 CD83 antigen
3004603_1 NM_013751 Hrasls HRAS-like suppressor
3003846_1 NM_008357 Il15 Interleukin 15
EXT_3106319_1 NM_008830 Abcb4 ATP-binding cassette, subfamily B (MDR/TAP), member 4
3004290_1 NM_008445 Kif3c Kinesin family member 3C
3003095_1 NM_010605 Kcnj5 Potassium inwardly-rectifying channel, subfamily J, member 5
3003615_1 NM_008185 Gstt1 Glutathione S-transferase, 	1
3003751_1 NM_009137 Ccl22 Chemokine (C-C motif) ligand 22
3002105_1 NM_008189 Guca1a Guanylate cyclase activator 1a (retina)
EXT_3109859_1 AK004546 Ostm1 Osteopetrosis-associated transmembrane protein 1
3003836_1 NM_008620 Mpa2 Macrophage activation 2
3004515_1 NM_008679 TRAM1 Nuclear receptor coactivator 3
3002967_1 NM_020258 Slc37a2 Solute carrier family 37 (glycerol- 3-phosphate transporter), member 2
EXT_3111717_1 NM_022964 Wbscr5 Williams-Beuren syndrome chromosome region 5 homolog (human)
3005715_1 NM_013563 Il2rg Interleukin 2 receptor,  chain
3002705_1 NM_007388 Acp5 Acid phosphatase 5, tartrate-resistant
MITF Regulation of Clcn7 andOstm1 in Osteoclasts
1898 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282•NUMBER 3•JANUARY 19, 2007
 at UQ Library on October 10, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
detection of MITF binding as well as the binding of its cotrans-
criptional activator, PU.1, on the Clcn7 promoter supports the
in vitro evidence that MITF directly regulates transcription of
Clcn7 in primary osteoclasts.
Radiolabeled oligonucleotide probes specific for the
M-boxes identified in the Clcn7 promoter were designed for
EMSA. A probe from the region of the TRAP promoter previ-
ously shown to have specific MITF binding (6) was used to
optimize conditions (Fig. 7B). Endogenous MITF from nuclear
extracts of RAW/C4 cells culturedwith sRANKL andCSF-1 for
5 days was found to bind specifically to probes 2, 3, and 4 as
shown by the supershift that occurs in the presence of a mouse
anti-MITF antibody (Fig. 7C). Binding specificity was demon-
strated using cold competition assays performed with the wild
type M-box oligonucleotides and mutated M-box oligonucleo-
tides in which the CANNTG core was mutated to CTCGAG.
Minor nonspecific bandswere present in the EMSA for probe 1.
Examination of the proximal promoters of the human, mouse,
and rat Clcn7 genes revealed that only M-boxes 3 and 4 are
conserved between these species (Fig. 7D). The EMSAs identify
specific sites of MITF binding (M-boxes 3 and 4) within the
Clcn7 promoter that are conserved between human, mouse,
and rat.
MITF but Not mi Expression Constructs Transactivate the
Clcn7 Promoter—Transient transfections of transcription fac-
tor expression plasmids were performed in RAW/C4 cells to
assess the activity and responsiveness of the proximal Clcn7
promoter. Mitf, mi, and empty vector expression constructs
were cotransfected with aClcn7 promoter (	731 to80) lucif-
erase reporter construct. The Clcn7 promoter was transacti-
vated by the wild typeMitf expression construct but not by the
mi (dominant negative) expression construct (Fig. 8). To deter-
mine which individual M-boxes are necessary for this transac-
tivation, specificM-boxmutant constructs were examined (Fig.
8). All of the four consensus M-boxes were mutated (M1–M4)
in separate constructs. Mutations of M1, M2, or M3 had no
effect on Clcn7 transactivation by MITF, although mutation of
M4, the site adjacent to the transcription start site, caused com-
plete inhibition of luciferase expression in cells transiently
transfected with wild typeMITF. Interestingly, mutation ofM3
reduced basal luciferase activity 2-fold, although this promoter
construct was still responsive to transient increases in wild type
MITF protein. A construct containing mutations of all four
M-boxes (M1–M4) had reduced levels of basal luciferase activ-
ity and was not responsive to transient overexpression of wild
type MITF protein. These data suggest that MITF transacti-
vates the Clcn7 promoter in vitro via M4. Basal expression of
Clcn7 involves M3 and unidentified factors but not MITF.
These EMSA and cell transfection assays demonstrate a con-
sistent ability of MITF to bind to and transactivate the Clcn7
promoter via at least one M-box.
MITF Binds and Transactivates the Ostm1 Promoter—
EMSA was performed on oligonucleotide probes specific for
the M-box identified in the Ostm1 promoter. Endogenous
MITF from nuclear extracts of RAW/C4 cells cultured with
sRANKLandCSF-1 for 5 days bound specifically to the probe as
shown by the supershift, which occurs in the presence of an
anti-MITF antibody (Fig. 9A). Binding specificity was demon-
strated using cold competition assays performed with a wild
typeM-box oligonucleotide and amutatedM-box oligonucleo-
tide in which the CANNTG core was mutated to CTCGAG.
These experiments thereby identified a specific MITF-binding
site within the Ostm1 promoter.
A 600-bp fragment of the murineOstm1 promoter (	534 to
63) was cloned into pGL2-Basic (pOstm1-Luc). The respon-
siveness toMITF of pOstm1-Luc was assayed by cotransfection
of the plasmid into RAW/C4 cells with an Mitf, mi, or empty
vector expression construct. TheOstm1 promoter was transac-
tivated by thewild typeMitf expression construct but not by the
mi expression construct (Fig. 9B). This indicates thatMITF can
activate transcription of a 600-bp fragment of the Ostm1 pro-
moter and that this is likely to bemediated throughMITF bind-
ing to the M-box identified within this region. The EMSA and
FIGURE 4. TRAP, Clcn7, and Ostm1 are up-regulated with similar kinetics
during osteoclastogenesis. qPCR for TRAP (A), Clcn7 (B), and Ostm1 (C) in
RAW/C4 cells cultured with sRANKL and CSF-1 over a time course of 7 days.
Expression of TRAP,Clcn7, andOstm1was induced after 3 days reachingmax-
imal expression between 5 and 7 days. All three genes display similar kinetics
of expression during the time course. Experiments were performed in tripli-
cate, and the bars represent the standard deviation for one experiment.
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FIGURE5.ClustalWalignmentof themouseandhumanClcn7andOstm1promoter regions.Theconservedpromoter regionsbetweenmouseandhumanhave
beenalignedfortheClcn7andOstm1genes.A,proximalpromoterregionoftheClcn7genecontains fourpotentialM-boxes.ThecandidateM-boxesare labeledM-box
1–4. M-boxes 1–3 occur in the 5 region upstream of the transcription start site, and M-box 4 is located in the 5-untranslated region immediately adjacent to the
transcriptionstartsite.B,candidateOstm1M-boxis labeledalongwiththreeotherweakMITF-bindingsites (E-boxes).Arrows indicatetranscriptionstartsites formouse
and human, and asterisks indicate the translation start sites. Conserved and aligned transcription factor-binding sites are boxed.
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cell transfection data indicate that MITF transcriptionally reg-
ulates the Ostm1 proximal promoter.
DISCUSSION
The differentiation of myeloid progenitor cells into bone-
resorbing osteoclasts depends upon lineage-specific extracellu-
lar signaling molecules, CSF-1, and RANKL. The binding of
these factors to their respective cognate receptors, CSF-1R
(c-Fms) and RANK, initiates changes in the pattern of tran-
scriptional regulation that direct changes in both the pheno-
type and activity of pre-osteoclasts and osteoclasts. MITF is a
member of the b-HLH-ZIPMiT subfamily of transcription fac-
FIGURE 6. qPCR analysis of TRAP and Clcn7mRNA levels. Bonemarrow-derived OCL from C57/BL6 andmi/mimice on a C57/BL6 background over a 5-day
culture with 40 ng/ml sRANKL and 104 units/ml CSF-1. Both TRAP and Clcn7 expression levels increased over the 5-day time course in the wild type mice. The
induction of both TRAP and Clcn7 expression was ablated in the mi/mi mice. Experiments were performed in triplicate, and the bars represent the standard
deviation for one experiment.
FIGURE 7. ChIP and EMSA confirm MITF binding to specific regions within the Clcn7 promoter. A, nuclear extracts were prepared from C57/BL6 bone
marrow cells following culturewith 40 ng/ml sRANKL and 1 104 units/ml CSF-1 over a period of 0–5 days. Using anti-MITF and anti-PU.1 antibodies to isolate
chromatin fragments, qPCRwas able to detect an increase in abundance of the Clcn7 promoter region bound to the respective proteins over the time course.
Experiments were performed in triplicate, and the bars represent the S.D. for one experiment. B, nuclear extracts from RAW/C4 cells treated with sRANKL and
CSF-1 (5 days) incubated with a probe from the TRAP promoter region to optimize EMSA conditions. WT, wild type; Mut, mutant; Ab, antibody; NS, not
significant.C, the samenuclear extractswere incubatedwith probes containing the fourM-boxes from theClcn7promoter region.MITFbinding specificitywas
demonstrated with cold competition with both wild type and E-box mutation oligonucleotides (arrow). Incubation with an anti-MITF antibody produces a
supershifted band (*). Selective loss of theMITF complex bywild type andnotmutant competitors suggests thatMITF has specificity forM-boxprobes 2, 3, and
4. No specific complex was seen in probe 1. D,M-boxes 3 and 4 are conserved between human, mouse, and rat species.
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tors that have been shown to regulate the process of gene
expression in osteoclasts (16). MITF forms heterodimers with
other MiT factors, TFE3, TFEB, and TFEC, to activate tran-
scription of its target genes. Terminally differentiated oste-
oclasts express all members of theMiT family of factors, so any
one of these factors is therefore capable of regulating gene
expression in osteoclasts (10).
The genes transcriptionally activated by MITF, including
TRAP (6, 19, 46) and cathepsin K (7), are late markers of oste-
oclastogenesis and have functional roles in bone resorption.
The function of TRAP in vivo remains unclear, but it appears to
regulate attachment of the osteoclast through dephosphoryla-
tion of v3 integrin phosphoprotein ligands, including
osteopontin and bone sialoprotein (53). TRAP participates in
reactive oxygen species-mediated hydrolysis of collagen
through the generation of OHradicals (54). Proteolytic nicking
of human TRAP can activate it as an ATPase at neutral pH
thereby potentially regulating the extracellular ATP concentra-
tion (55). On the other hand cathepsin K is the major cysteine
protease that hydrolyzes the collagen matrix. When cathepsin
FIGURE 8. Overexpression of wild type MITF protein, but not mi, transactivates Clcn7 promoter reporter constructs via a specific M-box. Clcn7
promoter-luciferase constructs are graphically represented (schematic) beside their respective relative luciferase activities (histogram). The four M-boxes
within the promoter have been mutated consecutively in separate constructs (M1–M4) and all together in one construct (M1–4). Vector refers to the empty
expression construct pEF6. Overexpression of MITF protein transactivates the wild type (WT), Clcn7pM1 (M1), Clcn7pM2 (M2), and Clcn7pM3-Luc (M3) reporter
constructs comparedwith basal levels. Basal levels (vector ormi) of luciferase reporter activity are reduced in transfection experimentswith theClcn7pM3- and
Clcn7pM1–4-Luc (M1–4) reporter constructs. Cotransfections with MITF were unable to transactivate Clcn7pM4-Luc or Clcn7pM1–4-Luc constructs. Bars
represent means S.E. (n 9).
FIGURE 9. EMSA confirmed MITF binding to an M-box containing probe within the Ostm1 promoter region, and MITF transactivates the Ostm1
promoter. A, nuclear extracts from RAW/C4 cells treated with sRANKL and CSF-1 (5 days) incubated with probes containing the M-box from the Ostm1
promoter region. MITF binding specificity was demonstrated with cold competition with both wild type (WT) and E-box mutation (Mut) oligonucleotides
(arrowhead). Incubation with an anti-MITF antibody produces a supershifted band (*). Selective loss of the MITF complex by wild type and not mutant
competitors suggests that MITF has specificity for the M-box probe. Ab, antibody. B, cotransfections with Mitf/pEF6 produce a 3-fold induction in relative
luciferase (Luc) activity compared with basal levels and transfections withmi/pEF6. Bars represent means S.E. (n 9).
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K is inactivated there is a profound loss of osteoclastic bone
resorption activity in both cathepsin K	/	mice (56) and in the
human disease, pycnodysostosis, where there are inactivating
mutations in the cathepsin K gene (57, 58).
To identify the set of osteoclast-expressed genes that are reg-
ulated by MITF, we have taken the approach of overexpressing
MITF in the RAW/C4 cell line. An alternative approach of
expressing the dominant negative mi was considered, but we
judged that the inactivation approach was likely to have more
profound consequences for osteoclast function based on the
biology of known MITF target genes as well as pleiotropic
effects on gene expression, which would make interpretation
more difficult. Expression of themi dominant negative form of
MITF in osteoclasts or in RAW/C4-derivedOCLwill inactivate
wild type MITF in homodimers and TFE3, TFEB, and TFEC as
heterodimers (9, 16). The effects of this dysregulation of the
MiT family on transcriptional control of MITF/TFE target
genes are likely to be more profound than that induced by ele-
vation of the level of MITF alone. The increase in MITF
through transient coexpression with promoter-reporter gene
constructs results in an increase in promoter activity of MITF
target genes in RAW264.7 macrophages and in the RAW/C4
subclone. Phosphorylation of MITF on Ser-307 by p38 MAP
kinase in response to RANKLbinding to RANK in osteoclasts is
required for transactivation of TRAP gene expression (19). The
gene induction observed with overexpression of MITF in
RAW/C4 cells indicates that the level of MITF is limiting for
target gene expression.
In this study, we have combined expression profiling with a
bioinformatic search for the presence of M-boxes, and as a
result we have identified a set of genes that are superinduced by
MITF overexpression in RAW/C4 cells undergoing osteoclas-
togenesis and contain candidate M-boxes in their promoter
regions. The regulation by MITF of two of these genes, the
chloride channel Clcn7 and theOstm1, was examined in detail.
Assays of functionality of the M-boxes by EMSA with nuclear
extracts of RAW/C4 cells confirmed that sites within the pro-
moters of Clcn7 andOstm1 could bindMITF as determined by
cold competition and supershifting with an anti-MITF anti-
body. The coordinate expression of these genes was examined
over a time course of osteoclastogenesis, and theywere induced
with similar kinetics to each other and to TRAP.
CLCN7 is a chloride channel localized to late endosomes,
lysosomes, and the ruffled border in osteoclasts, where it acts
with the vacuolar H-ATPase to acidify the resorptive space.
The loss or functional inactivation of CLCN7 causes osteope-
trosis as well as neurodegeneration and a severe lysosomal stor-
age disease (59). The G215R mutation in the human CLCN7
gene is associated with autosomal dominant osteopetrosis type
II, and patients are characterized by a loss of osteoclast function
despite no significant changes in the standard parameters of
osteoclast differentiation, phenotype, and the expression of
osteoclast markers (60).
The phenotype of Clcn7	/	 mice is strikingly similar to the
mutant grey-lethal gl/gl mice that are characterized by retinal
and central nervous system degeneration, pigmentation
changes, and osteopetrosis. The glmutation is a deletion result-
ing in complete loss of function of OSTM1 (61). The murine gl
gene encodes a 338-amino acid type I transmembrane protein
that localizes to the intracellular compartment.Mutation in the
humanGL (OSTM1) gene leads to severe recessive osteopetro-
sis. Characterization of an autosomal recessive malignant
infantile osteopetrosis individual revealed a homozygous 2-bp
deletion in exon 2 of OSTM1 and is characterized by severe
osteosclerosis, pathologic fractures, hepatosplenomegaly, and
pancytopenia (43). Activity of the murine gl protein is abso-
lutely required for osteoclast and melanocyte maturation and
function (61).
Recently the analysis of OSTM1 association with CLCN7
demonstrated that OSTM1 requires CLCN7 to localize to lyso-
somes, whereas the formation of a CLCN7-OSTM1 complex is
required to stabilize CLCN7 (44). In osteoclasts, OSTM1 and
CLCN7 colocalize with the a3 subunit of the V-type
H-ATPase in the ruffled border (44). The loss of osteoclast
function that occurs in the glmutation with the loss of OSTM1
may therefore result from a secondary reduction in CLCN7
protein levels. Clcn7 mRNA levels in gl mice are unchanged,
and Ostm1 mRNA levels are unchanged in Clcn7	/	 mice,
whereas the OSTM1 protein is undetectable in Clcn7	/	 oste-
oclasts (44). In our studies the basal level of Ostm1 was rela-
tively high but was further induced by RANKL treatment,
whereas the basal level of Clcn7 was very low but it was highly
inducible with RANKL treatment. Induction of Clcn7 during
osteoclastogenesis may induce association of a pre-existing
pool of OSTM1 and translocate to the lysozyme and from there
to the ruffled border.
In summary, we have used a cell line model of osteoclasto-
genesis in which we have increased the amount of MITF. The
superinduction of gene expression associated with both oste-
oclastogenesis and MITF overexpression was identified by
microarray analysis, and the list of candidateMITF target genes
was refined by bioinformatic analysis of the gene promoters for
candidate M-boxes. We identified the critical osteoclast func-
tional genes Clcn7 and Ostm1 as MITF targets and character-
ized the regulation by MITF of these genes.
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